Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration

Journal of Controlled Release

Volumn 97, Issue 3, 2004, Pages 421-429

  Wang, Xue Qing ^a   Dai, Jun Dong ^a   Chen, Zhen ^a   Zhang, Tao ^b   Xia, Gui Min ^b   Nagai, T ^c   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b North China Pharmaceutical Corporation   (China)

^c HOSHI UNIVERSITY   (Japan)

Author keywords

Bioavailability; Cyclosporine A; Nanoparticles; Oral administration; pH sensitive; Pharmacokinetics; Rats; Suspending agents

Indexed keywords

COLLOIDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOSTRUCTURED MATERIALS; PARTICLE SIZE ANALYSIS; PH EFFECTS; PHARMACOKINETICS;

BIOAVAILABILITY; DISSOLVED POLYMERS;

DRUG PRODUCTS;

CYCLOSPORIN A; HYDROXYPROPYLMETHYLCELLULOSE; NANOPARTICLE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; ENCAPSULATION; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MALE; MATHEMATICAL COMPUTING; MEAN RESIDENCE TIME; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; HYDROGEN-ION CONCENTRATION; MALE; NANOSTRUCTURES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3042551382     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.03.003     Document Type: Article

References (19)

1. Matzke G.R., Luke D.R. Dialysis and renal transplant therapy. Herfindal E.T., Gourley D.R., Hart L.L. Clinical Pharmacy and Therapeutics. 1988;229-242 Williams and Wilkins, Baltimore
2. Richardson C., Emery P. Clinical use of cyclosporin in rheumatoid arthiritis. Drugs. 50(suppl. 1):1995;26-36
3. Sajjadi H., Soheilian M., Ahmadieh H., Hussanein K., Parvin M., Azarmina M., Ehyaee V., Amiransari B. Low dose cyclosporin-A therapy in Behçet's disease. J. Ocul. Pharmacol. 10:1994;553-560
4. Luke D.R., Kasiske B.L., Matzke G.R., Awni W.M., Keane W.F. Effect of cyclosporin on the isolated perfused rat kidney. Transplantation. 43:1987;795-799
5. Cavanak T., Sucker H. Formulation of dosage forms. Prog. Allergy. 38:1986;65-72
6. Yanagawa A., Iwayama T., Saotome T., Shoji Y., Takano K., Oka H., Nakagawa T., Mizushima Y. Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres. J. Microencapsul. 6:1989;161-164
7. Urata T., Arimori K., Nakano N. Modification of the release rate of cyclosporin A from poly(L-lactic acid) microspheres by fatty acid ester and in vivo evaluation of the microspheres. J. Control. Release. 58:1999;133-141
8. Venkataram S., Awni W.M., Jordan K., Rahman Y.E. Pharmacokinetics of two alternative dosage forms of cyclosporin: liposomes and intralipid. J. Pharm. Sci. 79:1990;216-219
9. Sánchez A., Alonso M.J. Poly(D, L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood plasma levels of subcutaneously injected yclosporin A. Eur. J. Pharm. Biopharm. 41:1995;31-37
10. Bonduelle S., Pimienta C., Benoit J.P., Lenaerts V. Body distribution in mice of intravenously injected radiolabelled cyclosporin associated with polyisohexylcyanoacrylate nanocapsules or nanospheres. Eur. J. Pharm. Biopharm. 41:1995;27-30
11. Zhang Q., Yie G., Li Y., Yang Q., Nagai T. Studies on the cyclosporine A loaded stearic acid nanoparticcles. Int. J. Pharm. 200:2000;153-159
12. Molpeceres J., Guzman M., Aberturas M.R., Chacon M., Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci. 85:1996;206-213
13. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13:1996;1838-1845
14. Lee W.K., Park J.Y., Yang E.H., Suh H., Kim S.H., Chung D.S., Choi K., Yang C.W. Investigation of factors influencing the release rates of cyclosporine A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J. Control. Release. 84:2002;115-123
15. Saez A., Guzmán M., Molpeceres J., Aberturas M.R. Freeze-drying of polycaprolactone and poly(D, L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur. J. Pharm. Biopharm. 50:2000;379-387
16. El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int. J. Pharm. 249:2002;11-108
17. Jaeghere F.D., Allémann E., Kubel F., Galli B., Cozens R., Doelker E., Gurny R. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J. Control. Release. 68:2000;291-298
18. Eldridge J.H., Hammond C.J., Meulbroek J.A., Staas J.K., Gilley R.M., Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release. 11:1990;205-214
19. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13:1996;1838-1845